Understanding diabetes medications from the perspective of patients with type 2 diabetes - Prerequisite to medication concordance

被引:57
作者
Hayes, Risa P.
Bowman, Lee
Monahan, Patrick O.
Marrero, David G.
McHorney, Colleen A.
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Global Hlth Outcomes Res, Indianapolis, IN 46285 USA
[2] Indiana Univ, Sch Med, Dept Med, Div Biostat, Indianapolis, IN USA
[3] Indiana Univ, Sch Med, Div Endocrinol & Metab, Indianapolis, IN USA
[4] Merck & Co Inc, Outcomes Res & Management, West Point, PA USA
关键词
D O I
10.1177/0145721706288182
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose The purpose of this qualitative study was to explore diabetes medication experiences of patients with type 2 diabetes. Methods Study participants were recruited through newspaper advertisements and letters from primary and specialty clinics in Indianapolis, Indiana. The same professional facilitator conducted 18 focus groups (7 male, 11 female) at a Veteran Affairs facility in Indianapolis, Indiana. Participants were 138 socioeconomically diverse individuals with type 2 diabetes (68% female, 74% >= 50 years old, 61% non-Hispanic Caucasian). Participants were on a variety of diabetes medication regimens (61% injectable insulin monotherapy or in combination with orals). Content analysis of focus group transcripts was used to establish themes. Results Three major themes emerged across the focus groups: (1) the inconvenience and inflexibility of the timing and frequency of administration of many diabetes treatments on participants' lives, (2) the desire to avoid injections and/or insulin therapy, and (3) the physical and emotional side effects of diabetes medications. Assuming equivalent effectiveness of 2 medications, participants would weigh the convenience and flexibility, route of administration, side effects, and cost of the medications to arrive at a treatment preference. Participants believed they currently had no opportunity to express their treatment preference to their health care provider. Conclusions The best therapeutic option for a patient with type 2 diabetes will be one that is clinically effective and consistent with the patient's needs and preferences. The challenge for diabetes educators is to support patients in articulating and incorporating their needs and preferences into the treatment decision-making process.
引用
收藏
页码:404 / 414
页数:11
相关论文
共 40 条
[11]   Well-being and symptoms in relation to insulin therapy in type 2 diabetes [J].
de Sonnaville, JJJ ;
Devillé, W ;
Snoek, FJ ;
Wijkel, D ;
Colly, LP ;
Heine, RJ .
DIABETES CARE, 1998, 21 (06) :919-924
[12]   Taking medicines: concordance is not compliance [J].
Dickinson, D ;
Wilkie, P ;
Harris, M .
BRITISH MEDICAL JOURNAL, 1999, 319 (7212) :787-787
[13]   PREMIXED INSULIN PREPARATIONS IN PEN SYRINGES MAINTAIN GLYCEMIC CONTROL AND ARE PREFERRED BY PATIENTS [J].
DUNBAR, JM ;
MADDEN, PM ;
GLEESON, DT ;
FIAD, TM ;
MCKENNA, TJ .
DIABETES CARE, 1994, 17 (08) :874-878
[14]   Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes [J].
Freemantle, N ;
Blonde, L ;
Duhot, D ;
Hompesch, M ;
Eggertsen, R ;
Hobbs, FDR ;
Martinez, L ;
Ross, S ;
Bolinder, B ;
Stridde, E .
DIABETES CARE, 2005, 28 (02) :427-428
[15]   The problem with compliance in diabetes [J].
Funnell, MM ;
Anderson, RM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (13) :1709-1709
[16]   Patient empowerment: A look back, a look ahead [J].
Funnell, MM ;
Anderson, RM .
DIABETES EDUCATOR, 2003, 29 (03) :454-+
[17]   In diabetes care, moving from compliance to adherence is not enough - Something entirely different is needed [J].
Glasgow, RE ;
Anderson, RM .
DIABETES CARE, 1999, 22 (12) :2090-2092
[18]   How to read a paper - Papers that go beyond numbers (qualitative research) [J].
Greenhalgh, T ;
Taylor, R .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7110) :740-743
[19]   Dimensions of quality of life in people with non-insulin-dependent diabetes [J].
Hirsch, A ;
Bartholomae, C ;
Volmer, T .
QUALITY OF LIFE RESEARCH, 2000, 9 (02) :207-218
[20]   Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents [J].
Kadiri, A ;
Chraibi, A ;
Marouan, F ;
Ababou, MR ;
El Guermai, N ;
Wadjinny, A ;
Kerfati, A ;
Douiri, M ;
Bensouda, JD ;
Belkhadir, J ;
Arvanitis, Y .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1998, 41 (01) :15-23